Huakang Biomedical Holdings Company Limited

SEHK:8622 Stock Report

Market Cap: HK$75.1m

Huakang Biomedical Holdings Past Earnings Performance

Past criteria checks 0/6

Huakang Biomedical Holdings's earnings have been declining at an average annual rate of -1.2%, while the Medical Equipment industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 0.8% per year.

Key information

-1.2%

Earnings growth rate

0.6%

EPS growth rate

Medical Equipment Industry Growth13.7%
Revenue growth rate0.8%
Return on equity-10.8%
Net Margin-24.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11
Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Revenue & Expenses Breakdown

How Huakang Biomedical Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:8622 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2425-6203
31 Mar 2425-6213
31 Dec 2325-6203
30 Sep 2324-5193
30 Jun 2325-4193
31 Mar 2325-3193
31 Dec 2225-3192
30 Sep 2226-2183
30 Jun 2226-3183
31 Mar 2227-4183
31 Dec 2126-4182
30 Sep 2126-7182
30 Jun 2127-8192
31 Mar 2125-10212
31 Dec 2022-12212
30 Sep 2021-9212
30 Jun 2021-7202
31 Mar 2022-3182
31 Dec 19250162
30 Sep 1926-3162
30 Jun 1927-2142
31 Mar 19280121
31 Dec 18290111
31 Dec 1727-261
31 Dec 1625851
31 Dec 1519842

Quality Earnings: 8622 is currently unprofitable.

Growing Profit Margin: 8622 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8622 is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare 8622's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8622 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.3%).


Return on Equity

High ROE: 8622 has a negative Return on Equity (-10.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 20:55
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Huakang Biomedical Holdings Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution